1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

  • August 2015
  • -
  • Renub Research
  • -
  • 87 pages

Summary

Table of Contents

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.

This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)


Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)


1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak

Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)


Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)

1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics


Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
IMS Pharmaceutical Pricing & Reimbursement Concise Guide:  Brazil

IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Brazil

  • $ 1700
  • Industry report
  • March 2017
  • by IMS Health

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of ...

Entecavir Sales, Price Analysis, & Sales Forecast - 2017

Entecavir Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Entecavir Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Entecavir worldwide and by countries in North America, Europe, Japan, BRIC, ...

Lamivudine / Zidovudine Sales, Price Analysis, & Sales Forecast - 2017

Lamivudine / Zidovudine Sales, Price Analysis, & Sales Forecast - 2017

  • $ 1100
  • Industry report
  • April 2017
  • by Fore Pharma

Fore Pharma has released its new research, Lamivudine / Zidovudine Sales, Price Analysis, & Sales Forecast – 2017. Find out the sales of Lamivudine / Zidovudine worldwide and by countries in North America, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.